Barbara Ziffels

Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2

S. Wulhfard, Patrizia Murer, D. Neri, 2018, Clinical Cancer Research.

Detection of Soluble ED-A+ Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling

H. Figulla, C. Jung, D. Neri, 2016, Disease markers.

De novo expression of fetal ED-A+ fibronectin and B+ tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection

J. Gummert, H. Figulla, C. Jung, 2014, Journal of Molecular Histology.

Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.

D. Neri, Barbara Ziffels, Francesca Pretto, 2018, Immunotherapy.

A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas

A. Villa, A. Sannino, D. Neri, 2019, bioRxiv.

Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation.

D. Neri, Barbara Ziffels, B. Ziffels, 2019, Journal of biotechnology.

Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12.

D. Neri, Barbara Ziffels, D. Venetz, 2016, Protein engineering, design & selection : PEDS.

An antibody-based enzymatic therapy for cancer treatment: The selective localization of D-amino acid oxidase to EDA fibronectin.

L. Pollegioni, A. Grimaldi, S. Sacchi, 2021, Nanomedicine : nanotechnology, biology, and medicine.

Targeted delivery of interleukin-10 to chronic cardiac allograft rejection using a human antibody specific to the extra domain A of fibronectin.

J. Gummert, H. Figulla, C. Jung, 2015, International journal of cardiology.